查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726324

全球麻疹、腮腺炎和德国德国麻疹疫苗市场：市场规模、份额、趋势分析（按类型、目标人口、分销管道和地区）、细分市场预测（2025-2030 年）

Measles, Mumps, Rubella Vaccine Market Size, Share & Trends Analysis Report By Type, By Target Population, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

麻疹、腮腺炎和德国德国麻疹疫苗市场的成长和趋势：

根据Grand View Research, Inc.的最新报告，全球麻疹、腮腺炎和德国麻疹疫苗市场规模预计到2030年将达到29.5亿美元，2025年至2030年复合年增长率为8.47%。

这一增长得益于政府支持力道的加大和公共卫生宣传活动的发展。一个关键的转折点出现在 2025 年 4 月，当时长期对疫苗持怀疑态度的美国卫生局局长罗伯特·F·肯尼迪 (Robert F. Kennedy Jr.) 在德克萨斯州爆发麻疹疫情期间公开核准MMR 疫苗。在德克萨斯州发生第二例麻疹死亡病例后，甘乃迪国务卿公开放弃了对 MMR 疫苗的支持。甘乃迪的言论先前曾引发支持者的强烈反对，但在改变公众看法和强调 MMR 疫苗接种的重要性方面发挥了关键作用。这起事件对疫苗宣传活动起到了推动作用，提高了犹豫不决人群的接种依从性。这可以加强提高疫苗接种率，并最大限度地降低未来疫情爆发的风险，特别是在反疫苗接种情绪日益高涨的地区。

产品核可也是 MMR 疫苗市场的主要成长要素。 2022年6月，葛兰素史克宣布Priorix已获得美国食品药物管理局（FDA）核准，用于12个月及以上儿童的麻疹、腮腺炎和德国德国麻疹主动免疫。 Priorix 已在包括加拿大、澳洲和整个欧洲在内的 100 多个国家获得批准，并已透过全球 8 亿剂接种证明了其可靠性和广泛用途。 FDA 的核准为美国医护人员提供了默克公司 MMR II 疫苗的替代品，并增强了供应链的弹性，以满足全球疫情期间不断增长的需求。更多的选择也会增加竞争，从而有可能降低成本并提高可用性。此类监管部门的核准不仅证明了新疫苗的安全性和有效性，而且还透过促进医疗专业人员和犹豫不决的个人采用疫苗来扩大整体市场。

政府倡议继续在推动 MMR 疫苗市场成长方面发挥关键作用。 2025 年 2 月，新墨西哥州卫生部推出了专门的线上资源，以应对麻疹病例的惊人增长。该倡议的重点是提高人们的认识、发现当地疫情并教育人们及时接种疫苗的重要性。这代表着州和国家政府利用数位平台教育公民、打击错误讯息和为疫苗接种提供后勤支援的更广泛趋势。事实证明，政府主导的宣传活动、强制学前疫苗接种和增加免疫计画资金，对于降低疫情风险和确保全部区域预防非常有效。这些努力体现了全球对实现消除麻疹目标的政策承诺，尤其是在新冠疫情期间遭遇挫折之后。政府协调行动对于维持较高的疫苗接种覆盖率和确保公共卫生工作的成功仍然至关重要。

在亚太地区，当地製造商和公私合作在扩大 MMR 疫苗供应方面发挥关键作用。 2023 年 11 月，印度免疫学有限公司 (IIL) 推出了 Mabella 疫苗，这是与越南 Polyvac 研究所合作开发的麻疹-德国麻疹联合疫苗。这次疫苗发射正值印度人类生物学研究所成立25週年，标誌着印度为公民提供可负担疫苗的努力取得了重要里程碑。 Mabella 疫苗将支持印度的全民免疫计划（UIP），该计划每年惠及数百万儿童。透过提供国产、经济高效的疫苗替代品，此次推出的疫苗有可能提高疫苗接种覆盖率，特别是在服务不足的地区。此外，此类合作显示了该地区疫苗自给自足和创新的重要性。随着亚太地区越来越多的国家开发和批准自己的疫苗，该地区的疫苗市场将会蓬勃发展，减少对进口製剂的依赖，并加强医疗保健基础设施。

对抗局部疫情的疫苗接种计画也为市场扩张做出了重大贡献。例如，2024年11月，斯里兰卡卫生署针对麻疹病例的增加，针对某些地区启动了特别疫苗接种宣传活动。这项为期一周的计画旨在透过快速挨家挨户部署疫苗来遏制感染的蔓延，并专注于疫苗接种覆盖率下降的高风险地区。这些有针对性的干预措施表明，灵活、有针对性的策略可以迅速缩小免疫力差距并防止疾病復发。此类国家努力通常得到世界卫生组织和联合国儿童基金会等全球卫生组织的支持，进一步扩大了其影响力。这些有针对性的努力对于中低收入国家至关重要，因为这些国家的常规疫苗接种系统可能面临基础设施和财政挑战。这些宣传活动强调了应对力公共卫生政策的重要性，并表明即使是短期宣传活动也可以刺激市场需求，支持当地疫苗分发网络并有助于实现全球消除疾病的目标。

麻疹、腮腺炎和德国麻疹疫苗市场：概述

  • 按类型划分，四价疫苗将在 2024 年占据 57.37% 的收益占有率，预计在 2025 年至 2030 年期间将显着增长。这一快速增长的主要驱动力是对综合疫苗接种解决方案的需求不断增长，这些解决方案可以透过单剂疫苗预防多种疾病。
  • 根据目标人口，婴儿/幼儿（9-12 个月）细分市场将在 2024 年占据 67.96% 的最大市场占有率，预计在 2025 年至 2030 年间将大幅成长。
  • 按分销管道划分，疫苗中心和公共卫生诊所部门在 2024 年引领市场，占据 41.65% 的最大市场占有率。这些公共卫生机构，包括社区健康中心和政府经营的疫苗接种诊所，是 MMR 疫苗的主要提供者，尤其是在大多数人口依赖公共医疗保健的地区。印度的全民免疫计画（UIP）等政府资助的倡议进一步加强了卫生部门在免疫接种方面的重要作用。
  • 北美的麻疹、腮腺炎和德国德国麻疹疫苗市场占了最大的市场占有率，这得益于政府的大力努力和不断扩大的公共卫生倡议，旨在控制疫情并提高整个地区的疫苗接种覆盖率。

目录

第一章 分析方法与范围

第二章执行摘要

3. 麻疹、腮腺炎和德国德国麻疹疫苗市场：驱动因素、趋势和范围

  • 市场区隔和范围
  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场趋势与展望
  • 市场动态
    • 加强政府疫苗接种计划
    • 感染再次出现，疾病负担加重
    • 宣导和教育宣传活动
  • 市场限制因素分析
    • 疫苗犹豫和错误讯息
  • 按类型分類的分析工具
    • 波特五力分析
    • PESTEL分析
  • 市场机会分析
  • 新兴市场策略

第四章 麻疹、腮腺炎和德国德国麻疹疫苗市场：按类型估计和趋势分析

  • 麻疹、腮腺炎和德国德国麻疹疫苗市场：依类型波动分析
  • 按类型
  • 单一值
    • 单价疫苗市场（2018-2030）
  • 三价（混合 MMR）
    • 三价（MMR联合）疫苗市场（2018-2030）
  • 四价
    • 四价疫苗市场（2018-2030）

5. 麻疹、腮腺炎和德国德国麻疹疫苗市场：按目标人口细分的估计和趋势分析

  • 麻疹、腮腺炎和德国德国麻疹疫苗市场：按目标人口细分的趋势分析
  • 目标人口
  • 婴儿（9个月至12岁）
    • 婴幼儿市场（9个月至12岁）（2018-2030年）
  • 成人
    • 成人市场（2018-2030）

6. 麻疹、腮腺炎和德国德国麻疹疫苗市场：按通路分類的估值和趋势分析

  • 麻疹、腮腺炎和德国德国麻疹疫苗市场：通路的波动
  • 按分销管道
  • 医院和医疗机构
    • 医院和医疗机构市场（2018-2030）
  • 疫苗中心和公共卫生诊所
    • 疫苗中心和公共卫生诊所市场（2018-2030）
  • 小儿科/实用
    • 小儿科和私人诊所市场（2018-2030）

7. 麻疹、腮腺炎和德国德国麻疹疫苗市场：区域估计和趋势分析

  • 麻疹-腮腺炎-德国麻疹疫苗：各地区市场占有率（2024 年及 2030 年）
  • 各地区市场占有率分析（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 全球市场概况：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 北美麻疹、腮腺炎和德国德国麻疹疫苗市场（2018-2030 年）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲麻疹、腮腺炎和德国德国麻疹疫苗市场（2018-2030）
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太地区麻疹、腮腺炎和德国德国麻疹疫苗市场（2018-2030 年）
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 拉丁美洲麻疹、腮腺炎和德国德国麻疹疫苗市场（2018-2030 年）
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲麻疹、腮腺炎和德国德国麻疹疫苗市场（2018-2030 年）
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 战略地图
  • 公司市场占有率分析（2024年）
  • 公司简介
    • Merck &Co., Inc.
    • GSK
    • Serum Institute of India Pvt. Ltd.
    • Sanofi
    • Shanghai Institute of Biological Products
    • Beijing Institute of Biological Products
    • Biological E Ltd.
    • Sinovac
Product Code: GVR-4-68040-558-2

Measles, Mumps, Rubella Vaccine Market Growth & Trends:

The global measles, mumps, rubella vaccine market size is expected to reach USD 2.95 billion by 2030, registering a CAGR of 8.47% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is due to increasing government support and public health campaigns. A key turning point was in April 2025, when the U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, publicly endorsed the MMR vaccine amidst a surge in measles outbreaks in Texas. His public reversal and endorsement came after the second measles-related death in the state, drawing significant media attention and spurring nationwide discussion. Although it stirred backlash from segments of his prior supporter base, Kennedy's statement played a vital role in shifting public perception and reinforcing the importance of MMR vaccination. This event served as a catalyst for boosting vaccination campaigns and improving compliance among hesitant populations. High-profile endorsements can create powerful ripple effects across communities, strengthening efforts to increase immunization coverage and minimize the risk of future outbreaks, especially in areas facing rising anti-vaccine sentiment.

Product approval is another major growth driver in the MMR vaccine market. In June 2022, GSK announced that the U.S. Food and Drug Administration (FDA) approved its Priorix vaccine for active immunization against measles, mumps, and rubella in individuals aged 12 months and older. Already licensed in over 100 countries, including Canada, Australia, and across Europe, Priorix has distributed over 800 million doses globally, demonstrating its reliability and widespread use. Its FDA approval provided U.S. healthcare providers with an alternative to Merck's M-M-R II, enhancing supply chain resilience and meeting rising demand amid global outbreaks. The availability of more options also fosters competition, potentially reducing costs and improving accessibility. Regulatory approvals such as this not only validate the safety and efficacy of new vaccines but also expand the overall market by encouraging adoption among both healthcare professionals and hesitant individuals.

Government initiatives continue to play a central role in driving the MMR vaccine market growth. In February 2025, the New Mexico Department of Health launched a dedicated online resource in response to an alarming rise in measles cases. This initiative focused on raising awareness, identifying local outbreaks, and educating the public about the importance of timely vaccination. It represents a broader trend in which state and national governments are leveraging digital platforms to enhance public engagement, address misinformation, and support immunization logistics. Government-led awareness campaigns, school-entry vaccine requirements, and increased funding for immunization programs are proving effective in mitigating outbreak risks and ensuring community-wide protection. Such efforts reflect a global policy commitment to achieve measles elimination targets, especially after setbacks during the COVID-19 pandemic. Coordinated government action remains critical in maintaining high vaccination rates and ensuring the success of public health efforts.

In the Asia Pacific region, local manufacturers and public-private collaborations are playing a vital role in expanding MMR vaccine accessibility. In November 2023, Indian Immunologicals Limited (IIL) launched the Mabella vaccine-a measles and rubella combination vaccine developed in partnership with the Polyvac Institute of Vietnam. This launch coincided with the 25th anniversary of the Human Biologicals Institute and marked a significant milestone in India's efforts to provide affordable vaccines to its population. The Mabella vaccine supports India's Universal Immunization Programme (UIP), which targets millions of children annually. By offering a domestically produced, cost-effective alternative, this launch has the potential to strengthen vaccination coverage, especially in underserved regions. Moreover, such collaborations signify the importance of regional vaccine self-sufficiency and innovation. As more countries in Asia Pacific develop and license their own vaccines, the regional market is set to grow rapidly, reducing dependency on imported formulations and boosting health infrastructure.

Targeted immunization programs in response to localized outbreaks also contribute significantly to market expansion. For example, in November 2024, Sri Lanka's Ministry of Health initiated a special vaccination campaign targeting specific districts following a rise in measles cases. This week-long program focused on high-risk areas where immunization coverage had declined and aimed to contain the spread through rapid, door-to-door vaccine deployment. These focused interventions showcase how agile, targeted strategies can rapidly close immunity gaps and prevent disease resurgence. Such national initiatives often receive support from global health organizations like the WHO and UNICEF, further amplifying their impact. In low- and middle-income countries, where routine vaccination systems may face infrastructural or funding challenges, these targeted drives are crucial. They highlight the importance of responsive public health policies and demonstrate how even short-term campaigns can fuel market demand, support local vaccine distribution networks, and contribute to global disease elimination goals.

Measles, Mumps, Rubella Vaccine Market Report Highlights:

  • Based on type, the tetravalent segment accounted for the largest revenue share of 57.37% in 2024 and is anticipated to witness significant growth from 2025 to 2030. This surge is primarily fueled by the growing demand for comprehensive immunization solutions that provide protection against multiple diseases in a single dose.
  • Based on the targeted population, the infants and children (9 months to 12) segment dominated with the largest market share of 67.96% in 2024, and is anticipated to witness significant growth from 2025 to 2030, driven by increasing global immunization efforts and heightened awareness of vaccine-preventable diseases.
  • In 2024, the vaccine centers and public health clinics segment led the distribution channel category, capturing the largest market share at 41.65%. These public health facilities-including community health centers and government-run vaccination clinics-serve as primary providers of MMR vaccines, particularly in areas where public healthcare is the mainstay for most of the population. Their pivotal role in immunization delivery is further bolstered by government-funded initiatives, such as India's Universal Immunization Programme (UIP), which has played a critical part in broadening access to vaccines across the country.
  • The North American measles, mumps, and rubella vaccine market holds the largest market share, fueled by strong government efforts and expanded public health initiatives aimed at controlling outbreaks and increasing vaccination coverage across the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Targeted Population
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Targeted Population outlook
    • 2.2.3. Distribution Channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Measles, Mumps, Rubella Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Strengthened government immunization programs
    • 3.4.2. Resurgent outbreaks and rising disease burden
    • 3.4.3. Public awareness and education campaigns
  • 3.5. Market Restraint Analysis
    • 3.5.1. Vaccine hesitancy and misinformation
  • 3.6. Type Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
  • 3.7. Market Opportunity Analysis
  • 3.8. Market Emerging Strategies

Chapter 4. Measles, Mumps, Rubella Vaccines Market: Type Estimates & Trend Analysis

  • 4.1. Measles, Mumps, Rubella Vaccines Market: Type Movement Analysis
  • 4.2. Measles, Mumps, Rubella Vaccines Market Estimates and Forecast, by Type
  • 4.3. Monovalent
    • 4.3.1. Monovalent Market, 2018 - 2030 (USD Million)
  • 4.4. Trivalent (combined MMR)
  • 4.5. Tetravalent
    • 4.5.1. Trivalent (combined MMR) Market, 2018 - 2030 (USD Million)
  • 4.6. Tetravalent
    • 4.6.1. Tetravalent Market, 2018 - 2030 (USD Million)

Chapter 5. Measles, Mumps, Rubella Vaccines Market: Targeted Population Estimates & Trend Analysis

  • 5.1. Measles, Mumps, Rubella Vaccines Market: Targeted Population Movement Analysis
  • 5.2. Measles, Mumps, Rubella Vaccines Market Estimates and Forecast, by Targeted Population
  • 5.3. Infants and Children (9 months to 12)
  • 5.4. Adults
    • 5.4.1. Infants and Children (9 months to 12) Market, 2018 - 2030 (USD Million)
  • 5.5. Adults
    • 5.5.1. Adults Market, 2018 - 2030 (USD Million)

Chapter 6. Measles, Mumps, Rubella Vaccines Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Measles, Mumps, Rubella Vaccines Market: Distribution Channel Movement Analysis
  • 6.2. Measles, Mumps, Rubella Vaccines Market Estimates and Forecast, by Distribution Channel
  • 6.3. Hospitals and Healthcare Institutions
    • 6.3.1. Hospitals and Healthcare Institutions Market, 2018 - 2030 (USD Million)
  • 6.4. Vaccine Centers and Public Health Clinics
    • 6.4.1. Vaccine Centers and Public Health Clinics Market, 2018 - 2030 (USD Million)
  • 6.5. Pediatric and Private Healthcare Clinics
    • 6.5.1. Pediatric and Private Healthcare Clinics Market, 2018 - 2030 (USD Million)

Chapter 7. Measles, Mumps, Rubella Vaccines Market: Regional Estimates & Trend Analysis

  • 7.1. Measles, Mumps, Rubella Vaccines Market Share By Region, 2024 & 2030
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Regional Market Dashboard
  • 7.4. Global Regional Market Snapshot
  • 7.5. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.6. North America
    • 7.6.1. North America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.2. U.S.
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. U.S. Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.3. Canada
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Canada Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.4. Mexico
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Mexico Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7. Europe
    • 7.7.1. Europe Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.2. UK
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. UK Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.3. Germany
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Germany Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.4. France
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. France Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.5. Italy
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Italy Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.6. Spain
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Spain Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.7. Denmark
      • 7.7.7.1. Key Country Dynamics
      • 7.7.7.2. Competitive Scenario
      • 7.7.7.3. Regulatory Framework
      • 7.7.7.4. Denmark Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.8. Sweden
      • 7.7.8.1. Key Country Dynamics
      • 7.7.8.2. Competitive Scenario
      • 7.7.8.3. Regulatory Framework
      • 7.7.8.4. Sweden Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.9. Norway
      • 7.7.9.1. Key Country Dynamics
      • 7.7.9.2. Competitive Scenario
      • 7.7.9.3. Regulatory Framework
      • 7.7.9.4. Norway Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8. Asia Pacific
    • 7.8.1. Asia Pacific Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.2. Japan
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Japan Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.3. China
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. China Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.4. India
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. India Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.5. Australia
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Australia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.6. Thailand
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Thailand Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.7. South Korea
      • 7.8.7.1. Key Country Dynamics
      • 7.8.7.2. Competitive Scenario
      • 7.8.7.3. Regulatory Framework
      • 7.8.7.4. South Korea Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.9. Latin America
    • 7.9.1. Latin America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.9.2. Brazil
      • 7.9.2.1. Key Country Dynamics
      • 7.9.2.2. Competitive Scenario
      • 7.9.2.3. Regulatory Framework
      • 7.9.2.4. Brazil Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.9.3. Argentina
      • 7.9.3.1. Key Country Dynamics
      • 7.9.3.2. Competitive Scenario
      • 7.9.3.3. Regulatory Framework
      • 7.9.3.4. Argentina Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10. MEA
    • 7.10.1. MEA Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.2. South Africa
      • 7.10.2.1. Key Country Dynamics
      • 7.10.2.2. Competitive Scenario
      • 7.10.2.3. Regulatory Framework
      • 7.10.2.4. South Africa Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.3. Saudi Arabia
      • 7.10.3.1. Key Country Dynamics
      • 7.10.3.2. Competitive Scenario
      • 7.10.3.3. Regulatory Framework
      • 7.10.3.4. Saudi Arabia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.4. UAE
      • 7.10.4.1. Key Country Dynamics
      • 7.10.4.2. Competitive Scenario
      • 7.10.4.3. Regulatory Framework
      • 7.10.4.4. UAE Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.5. Kuwait
      • 7.10.5.1. Key Country Dynamics
      • 7.10.5.2. Competitive Scenario
      • 7.10.5.3. Regulatory Framework
      • 7.10.5.4. Kuwait Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Strategy Mapping
  • 8.4. Company Market Share Analysis, 2024
  • 8.5. Company Profiles
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. GSK
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Serum Institute of India Pvt. Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Sanofi
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Shanghai Institute of Biological Products
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Beijing Institute of Biological Products
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Biological E Ltd.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Sinovac
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Table

  • Table 1 List of abbreviations
  • Table 2 Global Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 3 Global Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 4 Global Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Measles, Mumps, Rubella Vaccines Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 9 North America Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 12 U.S. Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 15 Canada Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 18 Europe America Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 19 Europe America Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 UK Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 UK Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 22 UK Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Germany Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 24 Germany Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 25 Germany Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 France Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 France Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 28 France Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Italy Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 31 Italy Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Spain Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 34 Spain Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Denmark Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 37 Denmark Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Sweden Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 40 Sweden Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Norway Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 43 Norway Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Japan Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 50 Japan Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 China Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 China Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 53 China Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 India Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 India Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 56 India Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 Australia Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 Australia Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 59 Australia Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Thailand Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 62 Thailand Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 South Korea Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 South Korea Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 65 South Korea Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Latin America Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 67 Latin America Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 69 Latin America Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 Brazil Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 72 Brazil Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Mexico Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 75 Mexico Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 78 Argentina Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by type, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 85 South Africa Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 91 UAE Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Measles, Mumps, Rubella Vaccines Market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Measles, mumps, rubella vaccines market: Type movement analysis
  • Fig. 15 Measles, mumps, rubella vaccines market: Type outlook and key takeaways
  • Fig. 16 Monovalent market estimates and forecast, 2018 - 2030
  • Fig. 17 Trivalent (combined MMR) market estimates and forecast, 2018 - 2030
  • Fig. 18 Tetravalent market estimates and forecast, 2018 - 2030
  • Fig. 19 Measles, mumps, rubella vaccines market: Targeted Population movement analysis
  • Fig. 20 Measles, mumps, rubella vaccines market: Targeted Population outlook and key takeaways
  • Fig. 21 Infants and children (9 months to 12) market estimates and forecast, 2018 - 2030
  • Fig. 22 Adults (catch-up vaccination) market estimates and forecast, 2018 - 2030
  • Fig. 23 Measles, mumps, rubella vaccines market: Distribution channel movement analysis
  • Fig. 24 Measles, mumps, rubella vaccines market: Distribution channel outlook and key takeaways
  • Fig. 25 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 26 Hospitals and healthcare institutions market estimates and forecast, 2018 - 2030
  • Fig. 27 Vaccine centers and public health clinics market estimates and forecast, 2018 - 2030
  • Fig. 28 Pediatric and private healthcare clinics market estimates and forecast, 2018 - 2030
  • Fig. 29 Regional outlook, 2024 & 2030
  • Fig. 30 Global Measles, Mumps, Rubella Vaccines Market: Region movement analysis
  • Fig. 31 North America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 37 UK Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 38 France Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 42 Sweden Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 43 Norway Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 45 Japan Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 46 China Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 47 India Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 48 Australia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 50 Thailand Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 57 UAE Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)